Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 2Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Leukemia 1

Interventions

Cyclophosphamide 7Antilymphocyte Serum 7fludarabine phosphate 6Rituximab 6Filgrastim 6romidepsin 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Flow Cytometry 5Vorinostat 4Tacrolimus 4Gemcitabine 4Etoposide 4Cyclosporine 4Busulfan 4Bortezomib 4tanespimycin 3belinostat 3Whole-Body Irradiation 3Methylprednisolone 3Methotrexate 3Melphalan 3Lenalidomide 3Cord Blood Stem Cell Transplantation 3plerixafor 2nelarabine 2cobomarsen 2carfilzomib 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell, Cutaneous × RFT5-SMPT-dgA immunotoxin × Clear all
NCT00667017 2018-12-14

RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

University of Texas Southwestern Medical Center

Phase 2 Terminated
1 enrolled 1 chart
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡